- 期刊
- OpenAccess
Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer
並列摘要
Tyrosine kinases (TKs) play a significant role in cancerogenesis and cancer cell function. Initial developments in this field go back to the early 80s, but the success story really started with the selective BCR-ABL inhibitor, imatinib. Owing to the cancer-driving role of BCR-ABL in chronic myeloid leukemia (CML), excellent response rates lead to fast FDA approval in both the first and second treatments of CML patients. Since then, numerous TKs were identified. TK inhibitors have been developed accordingly, and technology to test for ideal drug-target interactions has profoundly improved. By now, medical oncologists and hematologists struggle to have a pool of potential TK inhibitors, where the most efficient one could be picked out to treat a specific cancer patient, which might also help overcome the occurring resistance mechanisms against TK inhibitors. Whether disease eradication can be achieved via single or sequential TK inhibitor treatment(s) needs to be tested in the present and in the future.
延伸閱讀
- Blau, O., Blau, I. W., & Afanasyev, B. (2015). Tyrosine Kinases in Cancer. Biomarker Insights, 2015(S3), 41-42. https://doi.org/10.4137/BMI.S34403
- 林志達（2014）。Exploring kinase inhibitor selectivity and binding mechanisms for anticancer drug development〔博士論文，國立交通大學〕。華藝線上圖書館。https://doi.org/10.6842/NCTU.2014.00789
- 商惠芳、陳作琳、林嘉伯、黃昭蓮（1995）。DNA Topoisomerases as Targets of Anticancer Drugs。藥物食品分析，3(3)，145-153。https://www.airitilibrary.com/Article/Detail?DocID=10219498-199509-3-3-145-153-a
- Crose, L. E. S., & Linardic, C. M. (2011). Receptor Tyrosine Kinases as Therapeutic Targets in Rhabdomyosarcoma. Sarcoma, 2011(), 420-430. https://doi.org/10.1155/2011/756982
- Druillennec, S., Dorard, C., & Eychène, A. (2012). Alternative Splicing in Oncogenic Kinases: From Physiological Functions to Cancer. Journal of Nucleic Acids, 2012(), 295-308. https://doi.org/10.1155/2012/639062